• Mashup Score: 1

    Duane Peters from the Lupus Foundation of America interviews Dr Jim Oates from the Medical University of South Carolina and Ralph H. Johnson VA Medical Center in Charleston, USA. They discuss his pape

    Tweet Tweets with this article
    • New #podcast Duane Peters @LupusOrg interviews Dr. Oates to discuss his paper on developing risk prediction models in #lupus #nephritis to predict outcomes at the point of# diagnosis, which can be used as support tool to help inform treatment strategies https://t.co/dyTp4ZQBxA

  • Mashup Score: 0

    Objectives Because a significant fraction of patients with lupus nephritis (LN) develops renal impairment, there is a need to better understand the mechanisms underlying disease progression. Here, we assessed for cellular senescence in the LN kidney, and its association with disease severity and outcome. Methods We enumerated the number of cells positive for p16INK4a protein, a marker of…

    Tweet Tweets with this article
    • Check out the our latest research on cellular senescence and #lupus: ▶️p16INK4a-positive cells as #senescence marker in #nephritis ▶️p16INK4a linked with renal fibrosis, CD8+ T cell infiltration and functional impairment 🔗https://t.co/joYf71r8DX https://t.co/HAdA6RKRnX

  • Mashup Score: 11

    The current treatment paradigm in lupus nephritis consists of an initial phase aimed at inducing remission and a subsequent remission maintenance phase. With this so-called sequential treatment approach, complete renal response is achieved in a disappointing proportion of 20–30% of the patients within 6–12 months, and 5–20% develop end-stage kidney disease within 10 years. Treat-to-target…

    Tweet Tweets with this article
    • How to choose agents in the changing landscape of #lupus #nephritis? Is precision medicinean option? 🔴Check out the latest viewpoint: From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? 🔗https://t.co/yKQ2hJOn4Y

  • Mashup Score: 0

    An initial median prednisone dose of 45 mg per day achieved significantly better complete renal response rates at 1 year in patients with new-onset lupus nephritis, according to data published in Arthritis Care & Research. “Given the numerous adverse events that may arise at any time after treatment initiation with glucocorticosteroids, current efforts are focused on minimizing their

    Tweet Tweets with this article
    • Starting with higher-dose #prednisone boosts 1-year renal response in #lupus #nephritis https://t.co/zBwKtohpr4 https://t.co/Pgz273ME86